A recent study showed that betulinic acid (BA) is capable of inhibiting cancer progression in two colorectal cancer lines, HCT116 and SW480, by interfering with the levels of pro-apoptotic markers, increasing the levels of cleaved Bax and caspase-3 and caspase-9, and decreasing those of the antiapoptotic Bcl2. The gene discussed is BCL2; the disease is cancer.